Every material Form 8-K Anixa Biosciences Inc has filed with the SEC since December 11, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its annual meeting on March 10, 2026, Anixa Biosciences stockholders re-elected four directors, approved executive compensation on a non-binding advisory basis, and ratified Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending October 31, 2026. The company also filed a presentation used by management at the meeting as Exhibit 99.1, which may be used in future investor meetings.
Shares present or represented by proxy: 20,805,324 of 33,379,505 shares entitled to vote
Executive compensation approved: 6,025,247 votes for, 2,973,752 against, 137,032 abstentions
Dr. Amit Kumar re-elected with 8,917,813 votes for and 218,238 withheld; the other three nominees received between 7,176,739 and 7,425,900 votes for
Auditor ratification: 20,426,524 votes for, 191,432 against, 187,368 abstaining
Anixa Biosciences said that 7 of 12 patients treated in its Phase 1 ovarian cancer CAR-T trial have lived beyond their expected median survival, and that regulators approved a protocol amendment allowing dose escalation. The company describes the survival evidence as encouraging but anecdotal, and says the trial is designed primarily to demonstrate safety. The filing contains no financial figures.
12 patients have been treated at four dosage levels; 7 have lived beyond their expected median survival of about three to four months
One patient survived 28 months, and three have survived more than one year (17, 15 and 14 months)
Amended protocol allows dosing up to 1×10⁹ cells/kg, from the original range of 1×10⁵ to 1×10⁷; no dose-limiting toxicities observed to date
Dr. Amit Kumar will discuss the trial at a Water Tower Research fireside chat on February 10, 2026, at 11:00am ET
On December 11, 2025, Anixa Biosciences and Cleveland Clinic presented final Phase 1 data for its investigational breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium. The company said the trial met all major primary endpoints, the vaccine was safe and well tolerated at the maximum tolerated dose, and 74% of participants showed protocol-defined immune responses. The filing discloses clinical results only, with no financial figures, and the data will inform planned Phase 2 study design.
Trial enrolled 35 participants across three cohorts; 74% of participants demonstrated protocol-defined immune responses
Primary adverse event was injection-site irritation; two participants in Cohort Ic had Grade 3 adverse events of greater injection-site irritation
Data will inform a planned Phase 2 study, including a potential neoadjuvant combination study with Keytruda in newly diagnosed breast cancer patients
Trial was funded by a grant from the U.S. Department of Defense and conducted with Cleveland Clinic
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Anixa Biosciences Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →